ByTrending Posts
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month…
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for CC-1234, its next-generation…
Atrium Therapeutics Spins Out with $270M Cash from…
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following Novartis’ $12 billion…
Azitra Spotlights ATR-12 Phase 1b Data at BIO…
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…
BioMarin’s Roctavian Withdrawal—$240M Q4 Charge, <200 U.S. Patients…
Published by BioNextAI Media – BioMarin Pharmaceutical Inc. voluntarily withdrew its pioneering hemophilia A gene therapy ROCTAVIAN (valoctocogene roxaparvovec-rvox)…
Boehringer’s Hernexeos Secures Record 44-Day FDA Nod via…
Published by BioNextAI Media – Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets) snagged ultra-fast FDA accelerated approval in just 44 days…
AbbVie’s $380M North Chicago API Expansion—300 Jobs, AI…
Published by BioNextAI Media – AbbVie is injecting $380 million into two new active pharmaceutical ingredient (API) facilities at…
Pfizer’s 1,200-GPU AI Blitz—$500M Bet to Slash 18-24…
Published by BioNextAI Media – Pfizer is deploying over 1,200 NVIDIA H100/H200 GPUs in a $500-600 million infrastructure overhaul,…
BioNextAI Media Report: Merck-Mayo Clinic AI Pact—5 Petabytes…
Published by BioNextAI Media – Merck has forged a high-octane research collaboration with Mayo Clinic, fusing 5 petabytes of…
BioNextAI Media Report: Keytruda’s Ovarian Cancer Combo Triumph—28%…
Published by BioNextAI Media – Merck’s KEYTRUDA (pembrolizumab) delivered compelling Phase 3 data from combination regimens in ovarian cancer,…
Trending Posts
Latest Stories
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for…
Atrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following…
Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO…
BioMarin’s Roctavian Withdrawal—$240M Q4 Charge, <200 U.S. Patients Served Amid Gene Therapy Market Reality Check
Published by BioNextAI Media – BioMarin Pharmaceutical Inc. voluntarily withdrew its pioneering hemophilia A gene therapy…
Gallery
